Selecta Biosciences Inc (NASDAQ:SELB) CEO Sells $21,836.16 in Stock

Selecta Biosciences Inc (NASDAQ:SELB) CEO Carsten Brunn sold 14,272 shares of Selecta Biosciences stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $1.53, for a total value of $21,836.16. Following the transaction, the chief executive officer now owns 85,186 shares in the company, valued at approximately $130,334.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Selecta Biosciences stock traded up $0.04 during mid-day trading on Tuesday, hitting $1.54. The company’s stock had a trading volume of 91,864 shares, compared to its average volume of 341,556. The stock’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.78. The firm has a market capitalization of $74.71 million, a PE ratio of -0.53 and a beta of 1.17. Selecta Biosciences Inc has a 1 year low of $1.28 and a 1 year high of $6.18.

Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Wednesday, November 13th. The company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. As a group, analysts predict that Selecta Biosciences Inc will post -1.23 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SELB. Millennium Management LLC increased its position in shares of Selecta Biosciences by 164.9% during the third quarter. Millennium Management LLC now owns 263,025 shares of the company’s stock valued at $460,000 after purchasing an additional 668,225 shares during the period. Jane Street Group LLC bought a new position in shares of Selecta Biosciences in the 2nd quarter worth $195,000. Morgan Stanley grew its position in shares of Selecta Biosciences by 582.4% during the 2nd quarter. Morgan Stanley now owns 63,784 shares of the company’s stock worth $114,000 after buying an additional 54,437 shares during the period. Paloma Partners Management Co bought a new stake in Selecta Biosciences in the second quarter valued at approximately $275,000. Finally, Vanguard Group Inc. boosted its position in shares of Selecta Biosciences by 7.3% during the second quarter. Vanguard Group Inc. now owns 1,620,305 shares of the company’s stock worth $2,901,000 after purchasing an additional 109,806 shares in the last quarter. Institutional investors and hedge funds own 38.42% of the company’s stock.

Several research analysts have recently weighed in on the stock. Mizuho reissued a “buy” rating and set a $4.00 price target on shares of Selecta Biosciences in a research report on Sunday, August 11th. Stifel Nicolaus restated a “buy” rating and set a $6.00 price objective on shares of Selecta Biosciences in a research report on Friday, November 8th. Zacks Investment Research downgraded shares of Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of Selecta Biosciences in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $6.80.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.

Further Reading: What is the S&P 500 Index?

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.